Background: CD19 direct chimeric antigen receptor (CAR) T-cell therapy is an efficacious therapy for patients (pts) affected by relapsed/refractory (R/R) large B-cell lymphomas (LBCL). The role of early evaluation by Positron emission tomography/computed tomography (PET/CT) is still undefined. The study's objective was to analyze the role of early PET/CT according to histology and CAR T-cell product administered.

Methods:CART-SIE is an ongoing prospective and retrospective observational study evaluating the outcome of lymphoma pts treated with CAR T-cells. From March 2019 to June 2023, 659 patients were enrolled. In this study, we included only pts with adequate follow-up (30 days) and an FDG-PET/CT before infusion (PET-0) and at least one month (PET-1) after CAR-T cells infusion. A landmark analysis based on PET-1 and PET-3 (3 months evaluation) results was performed for Progression-free survival (PFS) and Overall Survival (OS) estimation.

Results: Three hundred twenty-seven pts with R/R LBCL [n= 189 (58%) Diffuse large B-cell lymphomas, n= 59 (18%) High-grade B-cell lymphomas (HGBCL), n= 41 (13%) Primary Mediastinal B-cell lymphomas (PMBCL), n= 38 (11%) Mantle Cell Lymphoma (MCL)] received CAR T-cell treatment with axicabtagene-ciloleucel [n=161(49%), axicel], tisagenlecleucel [n=128 (39%), tisacel] or brexucabtagene autoleucel [n=38(12%), brexucel]. The median age of the pts was 58 years (90 pts were older than 65 years). Most pts [n=280, (85,6%)] were treated with a bridging therapy. Bulky and extranodal disease were observed in 108 (33%) and 177 (54,1%) pts, respectively. Pts who received tisacel were significantly older (p<0.0001), had a longer time from lymphocyte apheresis to the infusion (<0.0001), and did not include PMBCL. The median follow-up time was 12 months [IQR, 6,09-22,37]. At the time of PET-1, 180 pts (55%) showed a PET with DS1-3, 82(25%) had a PET with DS4 (n=61 PR, n=21 SD), and 65(20%) with DS5 (n=13 SD, n=47 PD, n=5 PR). The results of early PET were significantly different according to the histology (p<0.0005): the percentage of DS 4 and DS 5 was 22% and 23% for DLBCL, 30% and 31% for HGBCL, 39% and 7% for PMBCL, and 16% and 0% for MCL, respectively. Overall, 1-year PFS based on PET-1 was 67%, 42%, and 8% for DS1-3, DS4, and DS5 (p<0,0001), respectively. The prognostic role of DS 4 varied with histology: 1-year PFS was 36%, 58%, and 44% for DLBCL, PMBCL, and HGBCL (<0.0001), respectively. The outcome of early PET was significantly influenced by CAR T-cell product (also excluding PMBCL): 1-year PFS for pts with DS1-3 and DS4 at PET-1 was 66% and 51% for axicel and 58,7% and 32% for those treated with tisacel (p<0.0001). The 1-year OS based on PET-1 was 88%, 82%, and 33% for DS1-3, DS4, and DS5 (p<0,0001), respectively. At 90 days, only 219 pts were evaluable; 21 of 82 (26%) DS4 and 5 of 65 (8%) DS5 at PET-1 converted in CR. Overall, 1-year PFS and OS based on PET-3 was 80% and 93% for DS1-3, 64% and 93% for DS4, and 8% and 56% for DS5, respectively. Multivariable analyses identified DS4 and DS5 values on PET-1 and CAR T-cell product Tisacel associated with increasing risk of failure [HR: 1,95 (95%CI;1,01-3,76) for DS4; HR: 9,63 for DS5 (95%CI:6,13-15,13); p< 0,0001; HR: 1,53 for Tisacel vs Axicel; (95%CI:1,06-2,22); p<0.0231]. Conclusion: Early evaluation by PET significantly influenced the prognosis. Estimating the risk of failure must be integrated with CAR T- cell product.

Chiappella:Jannsen-Cilag: Other: lecture fee/educational activities, advisory board; Incyte: Other: lecture fee/educational activities; AstraZeneca: Other: lecture fee/educational activities; Takeda: Other: lecture fee/educational activities, advisory board; Ideogen: Other: advisory board; Roche: Other: lecture fee/educational activities, advisory board; Gilead-Sciences: Other: lecture fee/educational activities, advisory board; Novartis: Other: lecture fee/educational activities; Celgene-BMS: Other: lecture fee/educational activities, advisory board; SecuraBIO: Other: advisory board. Zinzani:MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC THERAPEUTICS: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BEIGENE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SECURA BIO: Membership on an entity's Board of Directors or advisory committees; CELLTRION: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; INCYTE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SANDOZ: Membership on an entity's Board of Directors or advisory committees; SERVIER: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; JANSSEN-CILAG: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GILEAD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASTRAZENECA: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TAKEDA: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSAPHARMA: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ROCHE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; KYOWA KIRIN: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Casadei:Lilly: Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees; Celgene-BMS: Membership on an entity's Board of Directors or advisory committees; Roche: Speakers Bureau; Novartis: Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite-Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Santoro:Servier: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy; Takeda: Speakers Bureau; Roche: Speakers Bureau; Merck MSD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eisai: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy; Abbvie: Speakers Bureau; Amgen: Speakers Bureau; Celgene (BMS): Speakers Bureau; AstraZeneca: Speakers Bureau; Eli Lilly: Speakers Bureau; Sandoz: Speakers Bureau; Novartis: Speakers Bureau; Arqule: Other. Di Rocco:Janssen: Honoraria; Takeda: Speakers Bureau; Abbvie: Honoraria; Incyte: Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Novartis: Speakers Bureau; Roche: Honoraria, Speakers Bureau. Carniti:Novartis: Other: travel expenses. Corradini:Novartis: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; Janssen: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; Nerviano Medical Science: Other: Honoraria (Consulting, advisory role, or lecturer); Kyowa Kirin: Other: Honoraria (Consulting, advisory role, or lecturer); Incyte: Other: Honoraria (Consulting, advisory role, or lecturer); Gilead/Kite: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; Daiichi Sankyo: Other: Honoraria (Consulting, advisory role, or lecturer); Celgene: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; Amgen: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; ADC Theraputics (DSMB): Other: Honoraria (Consulting, advisory role, or lecturer); AbbVie: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; Roche: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; Pfizer: Other: Honoraria (Consulting, advisory role, or lecturer); Sanofi: Other: Honoraria (Consulting, advisory role, or lecturer); SOBI: Other: Honoraria (Consulting, advisory role, or lecturer); Takeda: Other: Honoraria (Consulting, advisory role, or lecturer), Travel and accomodations; GlaxoSmithKline: Other: Honoraria (Consulting, advisory role, or lecturer); BeiGene: Honoraria; Bristol Myers Squibb: Other: Travel and accomodations.

This content is only available as a PDF.
2023
Sign in via your Institution